These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35238885)

  • 1. Nonhuman sugars cause factor VIII troubles.
    Hoffmeister KM
    Blood; 2022 Mar; 139(9):1262-1263. PubMed ID: 35238885
    [No Abstract]   [Full Text] [Related]  

  • 2. [INACTIVATION OF BLOOD THROMBOKINASE IN THE PRESENCE OF PROTHROMBIN AND FACTOR VIII].
    SCHIMPF K; BRIEGER G; OSAMO NO
    Klin Wochenschr; 1964 Feb; 42():134-7. PubMed ID: 14152613
    [No Abstract]   [Full Text] [Related]  

  • 3. SIPPET: insights into factor VIII immunogenicity.
    Fallon PG; Lavin M; O'Donnell JS
    J Thromb Haemost; 2018 Jan; 16(1):36-38. PubMed ID: 29080389
    [No Abstract]   [Full Text] [Related]  

  • 4. Clogging up the pipeline: factor VIII aggregates.
    Sabatino DE
    Blood; 2020 May; 135(21):1825-1827. PubMed ID: 32437559
    [No Abstract]   [Full Text] [Related]  

  • 5. Factor VIII forges its own path.
    Pratt KP
    Blood; 2023 Jul; 142(3):217-219. PubMed ID: 37471109
    [No Abstract]   [Full Text] [Related]  

  • 6. [Plasma transfusion in hemophilia. VIII. Effect of various plasma products on hemophilia A].
    van CREVELD ; MOCHTAR IA
    Ned Tijdschr Geneeskd; 1963 Jan; 107():155-9. PubMed ID: 14023830
    [No Abstract]   [Full Text] [Related]  

  • 7. CD36 regulates factor VIII secretion from liver endothelial cells.
    Reventun P; Toledano-Sanz P; Alcharani N; Viskadourou M; Morrison AC; Sabater-Lleal M; Wolberg AS; de Vries PS; Smith NL; Osburn WO; Arvanitis M; Lowenstein CJ
    Blood Adv; 2024 Jan; 8(1):143-149. PubMed ID: 38157226
    [No Abstract]   [Full Text] [Related]  

  • 8. [TECHNIC OF TRANSFUSION THERAPY IN SURGERY ON HEMOPHILIACS].
    ABDULLAEV GM; KOZHEVNIKOV IN
    Probl Gematol Pereliv Krovi; 1964 Aug; 9():36-40. PubMed ID: 14252414
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of classic hemophilia: the use of fibrinogen rich in factor VIII for hemorrhage and for surgery.
    MCMILLAN CW; DIAMOND LK; SURGENOR DM
    N Engl J Med; 1961 Aug; 265():277-83 concl. PubMed ID: 13774141
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative analysis of marketed factor VIII products: reply.
    Reipert BM; Anzengruber J; Scheiflinger F
    J Thromb Haemost; 2019 Jan; 17(1):233-235. PubMed ID: 30489690
    [No Abstract]   [Full Text] [Related]  

  • 11. von Willebrand factor and factor VIII in a healthy Brazilian population. Association with ABO blood groups.
    Valadares DF; Soares RRP; Di Giacomo G; Rocha T; Reichert CO; Bydlowski SP
    Thromb Res; 2020 Apr; 188():49-51. PubMed ID: 32058198
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative analysis of marketed factor VIII products: comment.
    Makris M; Farrugia A
    J Thromb Haemost; 2019 Jan; 17(1):232-233. PubMed ID: 30376211
    [No Abstract]   [Full Text] [Related]  

  • 13. Determinants of elevated factor VIII in patients screened for thrombophilia.
    Gajek A; Natorska J; Wypasek E; Stanisz A; Malinowski KP; Undas A
    Thromb Res; 2020 Apr; 188():28-30. PubMed ID: 32044504
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimizing factor VIII dosing in obese individuals with haemophilia A.
    Godby RC; Raju D; Massicano F; Williams LA; Black B; Dorn D; Marques MB
    Blood Coagul Fibrinolysis; 2021 Oct; 32(7):528-530. PubMed ID: 34285174
    [No Abstract]   [Full Text] [Related]  

  • 15. Getting under the skin: a new route for factor VIII?
    McKinnon TAJ
    Blood; 2021 Feb; 137(8):1007-1008. PubMed ID: 33630048
    [No Abstract]   [Full Text] [Related]  

  • 16. A METHOD FOR THE ASSAY OF FACTOR V.
    BLOMBAECK B; BLOMBAECK M
    Scand J Clin Lab Invest; 1963; 15():639-48. PubMed ID: 14077019
    [No Abstract]   [Full Text] [Related]  

  • 17. Increasing levels of von Willebrand factor and factor VIII with age in patients affected by von Willebrand disease: REPLY from original authors Biguzzi et al.
    Biguzzi E; Siboni SM; le Cessie S; Baronciani L; Rosendaal FR; van Hylckama Vlieg A; Peyvandi F
    J Thromb Haemost; 2021 Jan; 19(1):310. PubMed ID: 33405387
    [No Abstract]   [Full Text] [Related]  

  • 18. The factor VIII treatment history of non-severe hemophilia A-Response from original authors Abdi et al.
    Kloosterman FR; Abdi A; Gouw SC; Hart DP; Fijnvandraat K
    J Thromb Haemost; 2021 Oct; 19(10):2642-2644. PubMed ID: 34558782
    [No Abstract]   [Full Text] [Related]  

  • 19. Surgery in mild haemophilia A patients with a history of inhibitor antibodies against factor VIII: Individualized management.
    Poon MC; Goodyear MD; Rydz N; Lee A
    Haemophilia; 2021 Nov; 27(6):e768-e771. PubMed ID: 34529880
    [No Abstract]   [Full Text] [Related]  

  • 20. Endothelial Dysfunction, Atherosclerosis, and Increase of Von Willebrand Factor and Factor VIII: A Randomized Controlled Trial in Swine.
    Lämmle B
    Thromb Haemost; 2021 May; 121(5):552. PubMed ID: 33412594
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.